Lilly Acquires Rights To TRPV-1 Receptor Antagonists From Glenmark
This article was originally published in The Pink Sheet Daily
Executive Summary
Portfolio includes Phase II candidate GRC 6211 for treatment of pain conditions, including osteoarthritic pain.